PRTO - Proteon Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.9900
+0.0200 (+0.67%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.9700
Open3.0000
Bid2.93 x 900
Ask3.17 x 1000
Day's Range2.9700 - 3.0500
52 Week Range1.5000 - 3.1000
Volume214,558
Avg. Volume72,377
Market Cap57.472M
Beta (3Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)-1.19
Earnings DateMar 12, 2019 - Mar 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.80
Trade prices are not sourced from all markets
  • ACCESSWIRE3 days ago

    4 Healthcare Stocks Looking To Set February Highs

    CORAL GABLES, FL / ACCESSWIRE / February 12, 2019 / The healthcare stock market's success is intrinsically connected to victories of companies working in the healthcare industry. With the advent of new medical technologies and an influx of doctors considering alternative forms of treatment previously thought to be ineffective, the healthcare industry is buzzing with excitement. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aurora Cannabis Inc (NYSE: ACB, TSX: ACB), Pyxus International Inc (PYX), and Proteon Therapeutics Inc (PRTO) represent four healthcare companies operating with the consumer's best interests in mind.

  • GlobeNewswire22 days ago

    Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease

    Proteon Therapeutics Inc. (PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced the publication in the Journal of Vascular Surgery of results from its Phase 3 PATENCY-1 clinical trial of investigational vonapanitase. The study results suggested vonapanitase may improve both fistula use for hemodialysis and secondary patency (time to fistula abandonment), which are the co-primary endpoints in Proteon’s ongoing Phase 3 PATENCY-2 clinical trial.

  • Does The Proteon Therapeutics, Inc. (NASDAQ:PRTO) Share Price Fall With The Market?
    Simply Wall St.2 months ago

    Does The Proteon Therapeutics, Inc. (NASDAQ:PRTO) Share Price Fall With The Market?

    If you own shares in Proteon Therapeutics, Inc. (NASDAQ:PRTO) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • Associated Press3 months ago

    Proteon Therapeutics: 3Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 25 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • Is Proteon Therapeutics Inc (NASDAQ:PRTO) A Strong Healthcare Bet?
    Simply Wall St.5 months ago

    Is Proteon Therapeutics Inc (NASDAQ:PRTO) A Strong Healthcare Bet?

    Proteon Therapeutics Inc (NASDAQ:PRTO), a US$39.0m small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population,Read More...

  • Associated Press6 months ago

    Proteon Therapeutics: 2Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 28 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • Proteon Therapeutics Inc’s (NASDAQ:PRTO) Earnings Dropped -27.47%, How Did It Fare Against The Industry?
    Simply Wall St.9 months ago

    Proteon Therapeutics Inc’s (NASDAQ:PRTO) Earnings Dropped -27.47%, How Did It Fare Against The Industry?

    Measuring Proteon Therapeutics Inc’s (NASDAQ:PRTO) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceedRead More...

  • ACCESSWIRE9 months ago

    Blog Exposure - Proteon Extended Long-term Contract with Lonza for Commercial Supply of Vonapanitase's Active Pharmaceutical Ingredient

    LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Proteon Therapeutics, Inc. (NASDAQ: PRTO), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PRTO as the Company's latest news hit the wire. On May 8, 2018, the Company announced that it has extended its long-term contract with Lonza Pharma & Biotech for the commercial supply of investigational vonapanitase's active pharmaceutical ingredient (API). Active-Investors.com is currently working on the research report for BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), which also belongs to the Healthcare sector as the Company Proteon Therapeutics.

  • Proteon Therapeutics Inc (NASDAQ:PRTO): Are Analysts Optimistic?
    Simply Wall St.11 months ago

    Proteon Therapeutics Inc (NASDAQ:PRTO): Are Analysts Optimistic?

    Proteon Therapeutics Inc’s (NASDAQ:PRTO): Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The US$39.64MRead More...